WhatsApp Intervention to Assess the Effect of Messages in Adherence to Antiretrovirals in Young People with HIV in Peru
- Conditions
- HIV
- Interventions
- Behavioral: Standardized messagesBehavioral: Self-designed messages
- Registration Number
- NCT06500013
- Lead Sponsor
- Universidad Peruana Cayetano Heredia
- Brief Summary
The goal of this clinical trial is to learn which type of messages is more efficacious to improve adherence to medication in young people living with HIV. The main question is aims to answer is:
-Are messages designed by participants (self-designed) more efficacious than messages designed by health providers to improve adherence to antiretroviral treatment (HIV medications)?
Researchers will compare both types of messages to see if one is better than the other in helping participants take their medications.
Participants will:
* Receive either messages designed by themselves or by health providers for 4 months.
* Be able to chat with health providers at any time, with special focus regarding questions about their condition, medications and health services.
* Complete questionnaires via WhatsApp describing how they are taking their medications, and how often they forget to take them.
* Complete questionnaires via WhatsApp describing their opinion about receiving the messages and being able to chat with health providers.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 131
- People living with HIV of age 18-29 at the moment of signing informed consent.
- Being a patient of the study center's Infectious Diseases clinic or National HIV Program, between March 2024 and July 2024.
- Ownership of a mobile phone that supports WhatsApp.
- Being pregnant at the moment of signing informed consent.
- Being illiterate at the moment of signing informed consent.
- Being blind at the moment of signing informed consent
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Standardized messages Standardized messages This group of participants will receive messages designed by researchers based on behavioral change theories, up to 3 times a week in the day and time of their choosing, for 16 weeks. Self-designed messages Self-designed messages This group of participants will design their own messages, and receive them via mobile messaging up to 3 times a week in the day and time of their choosing, for 16 weeks.
- Primary Outcome Measures
Name Time Method Change from Baseline in the Result of SMAQ Questionnaire Adjusted for the Effect of Covariables Baseline, 16 weeks. The SMAQ questionnaire evaluates medication adherence. It provides a dichotomic result of adherence (yes/no), and a semiquantitative estimate of adherence. Greater than 95% adherence is considered as adherent, and less than 95% as non-adherent.
- Secondary Outcome Measures
Name Time Method ART adherence measured by SMAQ Questionnaire at 4, 8 and 12 weeks of intervention 4, 8 and 12 weeks of intervention SMAQ provides a dichotomic result of adherence (yes/no): we will report percentage of participants adherent to ART per study group during the intervention.
Loss to follow-up From the start of delivery intervention until study completion Loss to follow-up is defined as either (i) participants not responding to messages for ≥ 30 continuous days since receiving the intervention and not responding to messages or questionnaires at the end of their intervention period (t=16), or (ii) particip
Time of permanence in the study Baseline until study completion (16 weeks). Time of permanence in the study, indicated from the first date of intervention delivery until loss to-follow up or study completion. We will describe the median and interquartile range of this result in both study arms.
Metrics on the use of a bidirectional platform for intervention delivery End of the intervention at 16 weeks. Frequencies, percentages, and means with a standard deviation of messages and questionnaires programmed for sending, sent, received, read, and answered by participants. Frequencies and percentages of different process indicators self-reported by participants.
Trial Locations
- Locations (1)
Hospital Cayetano Heredia
🇵🇪Lima, Peru